Listed Indian subsidiary of Pfizer selling branded pharmaceuticals, vitamins and vaccines domestically.
Listed Indian subsidiary of Pfizer selling branded pharmaceuticals, vitamins and vaccines domestically.
Majority-owned by Pfizer Inc, it sells long-standing local brands and Pfizer's global products through wholesalers to pharmacies and hospitals. Sales depend on doctors' prescriptions and on Indian price controls on essential medicines, which set ceilings for many drugs.
In one line: Pfizer's Indian pharma subsidiary.
Moat: narrow (brand). Established consumer trust in legacy brands like Becosules, though the portfolio is narrower than global Pfizer.
Headquarters: Mumbai, India · Founded: 1950 · Employees: 1,417
Size Pfizer (PFIZER.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.88B, the 394th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹3,842 on 18 Nov 2026.
Performance Over six months the shares fell 19.7%, against -7.3% for the median peer and +3.8% for the India market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 11.8% over the last twelve months (peer median +10.7%); the operating margin is 34.5% (peer median 13.3%).
Valuation It trades at 21.9× forward earnings against a peer median of 16.9× (8th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 35.3 points above its cost of capital (13.2% WACC).
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹26.5B | ₹25.2B | ₹22.8B | ₹21.9B | ₹24.2B |
| Revenue growth | — | +10% | +4% | -10% | — |
| Gross profit | ₹12.6B | ₹11.5B | ₹9.86B | ₹9.37B | ₹10.6B |
| EBITDA | ₹9.73B | ₹9.21B | ₹7.58B | ₹6.54B | ₹8.28B |
| Net income | ₹8.59B | ₹7.22B | ₹7.68B | ₹5.51B | ₹6.24B |
| Free cash flow | n/a | ₹11.2B | ₹7.71B | ₹3.66B | ₹3.61B |
| Capital expenditure | n/a | ₹252M | ₹282M | ₹189M | ₹650M |
| Total debt | ₹1.97B | ₹702M | ₹1.08B | ₹945M | ₹1.34B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Pfizer PFIZER.NS | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% |
| Abbott India ABBOTINDIA.NS | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% |
| Sanofi India SANOFI.NS | $797M | 0% | -6% | 26% | 19.6× | 16.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PFIZER.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.9% | +1.5% | 11th highest of 21 |
| 6-month return | -19.7% | -7.3% | 7th lowest of 21 |
| Distance from 52-week high | -28.0% | -27.9% | 11th highest of 21 |
| Revenue growth (TTM) | +11.8% | +10.7% | 10th highest of 20 |
| Operating margin | 34.5% | 13.3% | highest of 20 |
| Forward P/E | 21.9× | 16.9× | 8th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 11.2% | 0.3% | 3rd most demanding of 13 |
| Growth delivered (Del g) | +2.4% | +7.7% | 3rd lowest of 13 |
| Hurdle (Req g minus delivered) | +8.8 pp | -12.1 pp | 3rd most demanding of 13 |
| ROIC minus cost of capital | +35.3 pp | +0.1 pp | highest of 20 |
| EV / EBITDA | 15.0× | 18.2× | 5th cheapest of 10 |
| Net debt / EBITDA | -3.1× | 1.2× | least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.80B | -12% | -6% | 8% | 25.8× | -0.7% | +0.5% |